← Back to screener

Sarepta Therapeutics, Inc. SRPT

Rank #2368 · Nasdaq · $2.0B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
21.8
P/E
-3.7
P/B
5.11
ROE
-139.2%
Op. Margin
-21.5%
Debt Ratio
633%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -3.7x, P/B 5.11x. Ranks in the top 78% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -139.2%. Ranks in the top 89% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 633%. Ranks in the top 83% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★☆
Excellent

Revenue growth of 33.3% year over year. Ranks in the top 11% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$-0.0B–-1732
2012–$-0.0B$-0.0B$0.0B–75
2013–$-0.0B$-0.0B$0.1B–66
2014–$-0.0B$-0.1B$0.2B–18
2015–$-0.1B$-0.1B$0.2B–19
2016$0.0B$-0.1B$-0.1B$0.2B-1371.244
2017$0.0B$-0.2B$-0.2B$0.2B-17572.535
2018$0.0B$-0.3B$-0.3B$0.2B-4920.3273
2019$0.2B$-0.2B$-0.1B$0.3B-111.0181
2020$0.3B$-0.3B$-0.4B$0.8B-114.1127
2021$0.4B$-0.7B$-0.7B$1.0B-185.3215
2022$0.5B$-0.6B$-0.6B$0.8B-104.5271
2023$0.7B$-0.5B$-0.4B$0.8B-65.5360
2024$0.9B$-0.5B$-0.7B$0.9B-57.5259
2025$1.2B$-0.3B$-0.5B$0.4B-21.5633

← See the full screener